Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.

@article{Gheorghiade2011PharmacokineticsAP,
  title={Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.},
  author={Mihai Gheorghiade and An Thyssen and Robert Zolynas and Venkatesh K Nadar and Barry H. Greenberg and Mandeep Mehra and Xiang Sun and Hong Tian and Alexei Nikolaevich Plotnikov and Paul Bryan Burton},
  journal={The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation},
  year={2011},
  volume={30 2},
  pages={218-26}
}
BACKGROUND Heart failure (HF) is associated with a hypercoagulable state that predisposes to thromboembolism and anti-coagulation may improve clinical outcomes. The oral, direct Factor Xa inhibitor, rivaroxaban, has not been studied in patients with HF. We hypothesized that rivaroxaban would also reduce biomarkers of hypercoagulability in patients with HF. METHODS This study consisted of two cohorts: Cohort 1, open-label, actively controlled with enoxaparin 40 mg once daily, included 8… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series

Journal of Thrombosis and Thrombolysis • 2017
View 6 Excerpts
Highly Influenced

Biomarkers for severe eosinophilic asthma.

The Journal of allergy and clinical immunology • 2017

Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…